Pfizer Inc stated on Tuesday that sales forecast for the anti-COVID-19 vaccine increased by 7.5%, reaching USD36 billion for 2021, according to Reuters.
According to the World Health Organization (WHO), Pfizer BioNTech’s vaccine is proven 95% effective against symptomatic SARS-CoV-2 infection, as its antibodies last for a long time, for at least 6 months, leading scientists to think about a third booster shot.
Pfizer’s shots become one of the best-selling anti-COVID-19 products, leading to the increase in deals with several countries around the world, including Morocco, especially for the use of Pfizer as third booster shots.
Recently, the company has started a large study testing its new oral antiviral drug PF-07321332 to prevent COVID-19 infections, the company said on its website.
The company’s CEO said PF-07321332 is a potential oral therapy that could be prescribed at the first sign of infection, without requiring patients to be hospitalized or in critical care, the two have the potential to create an end to the treatment paradigm that complements vaccination in cases where the disease still occurs.
In July, the company had forecast sales of USD33.5 billion for BioNTech vaccines.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.